Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

(2014) Brian H. Kushner et al.   CLINICAL CANCER RESEARCH

Key role for myeloid cells: Phase II results of anti-GD2antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

(2014) Nai-Kong V. Cheung et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

(2014) Fariba Navid et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy

(2013) Mahiuddin Ahmed et al.   FEBS LETTERS

Current and Future Strategies for Relapsed Neuroblastoma

(2013) Daniel A. Morgenstern et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

(2013) Susan G Kreissman et al.   LANCET ONCOLOGY

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

Ifosfamide, carboplatin, and etoposide for neuroblastoma

(2012) Brian H. Kushner et al.   CANCER

New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome

(2012) K. A. Cole et al.   CLINICAL CANCER RESEARCH

Promising Therapeutic Targets in Neuroblastoma

(2012) K. K. Matthay et al.   CLINICAL CANCER RESEARCH

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

(2011) Wendy B. London et al.   JOURNAL OF CLINICAL ONCOLOGY

Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study

(2011) Julie R. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor

(2011) Irene Y. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

(2010) Suzanne Shusterman et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan

(2010) Brian H. Kushner et al.   PEDIATRIC BLOOD & CANCER

Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials

(2010) Thorsten Simon et al.   PEDIATRIC BLOOD & CANCER

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry

(2009) Alberto Garaventa et al.   EUROPEAN JOURNAL OF CANCER

Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma

(2009) Brian H. Kushner et al.   JOURNAL OF CLINICAL ONCOLOGY

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

(2009) Kim Kramer et al.   JOURNAL OF NEURO-ONCOLOGY

Disease control intervals in high-risk neuroblastoma

(2008) Victor M. Santana et al.   CANCER

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

(2008) Andrew DJ Pearson et al.   LANCET ONCOLOGY